Endocrine Abstracts

Background: Immunotherapy with checkpoint inhibitors (CPI) {CTLA4 and PD-1 inhibitors} have significantly improved outcomes and survival rates in patients with a number of cancers. In the UK, Ipilimumab and Nivolumab are approved for the treatment of advanced malignant melanoma. These are often long term therapies and are associated with immune mediated endocrinopathies.Case: A 70 year old male presented to the Medical Admissions Unit with a history of l...